Germline carriers of deleterious BRCA2 mutations that commonly truncate the encoded protein exhibit an increased lifetime risk of developing PDAC, in addition to their well‐known predisposition to cancers of the breast and ovary (Breast Cancer Linkage Consortium, 1999). This evidence concerns the gene BRCA2 and cancer.